Hemoglobinopathy Institute

Hemoglobinopathy Institute (HI), a part of the DRT, is the medical research agency making important discoveries that improve health and save lives.

Director

Dr. Hossein Ranjbaran

E-Mail: ho.ranjbaran@gmail.com

ISID

Scopus

Scholar

History

Hemoglobinopathy Institute is a scientific-research center affiliated to Mazandaran University of Medical Sciences that works in the field of blood diseases. The establishment of this institute was approved in November 1, 2012 to form a group of researchers and faculty members of the universities. Its objectives and statute were affirmed according to the decision issued in the 250th session of Council of Expansion of Medical Sciences Universities on November 22, 2015.

Vision

• Developing relationship with other research institutes and research centers in the university
• Developing research relationship with other universities in the country
• Using the dedicated budget to conduct research projects to keep up with the world
• Supporting noble students research projects
• Engaging active human resources and faculty members
• Holding workshops and periodical training courses related to blood diseases 

Mission

-  Research-educational mission:

  i) Making relationship with other domestic and foreign research centers

      (a) Detecting the domestic and foreign active centers that work on blood diseases

      (b) Making relationship with the centers to conduct research projects to have collaborative products or services

      (c) Working on the possibility of student/faculty member exchange in the areas of high priority

   ii) Holding congress on blood diseases

     (a) Holding journal clubs

     (b) Holding specialized workshops

     (c) Setting up the website of the institute

     (d) Preparing educational pamphlets for physicians and patients

- Establishing a referral diagnostic-research laboratory for blood disorders

  i) Investigating the frequency of major hemoglobinopathies in the region

  ii) Determining the alpha and beta thalassemia mutations using NGS and making relationship with foreign research centers

  iii) PND and determining the problems and deficiencies

  iv) Investigating the molecular defects of coagulation diseases and specialized coagulation tests

  v) A referral diagnostic-research center for leukemia

  vi) Investigating the prognosis factors in leukemia
  vii)Making a specialized site in the institute for counselling, research, diagnostic-treatment services 

Goals

- Organizing disease registry

   i) Recording laboratory and clinical information of the patients

     (a) Following up the thalassemic patients registration

     (b) Feasibility study of the disease registrations such as hemophilia

   ii) Preparing biobank (serum, cell, DNA, RNA, …) iii) HLA bank

- Development and improvement of treatment methods in blood disorders

   i) Producing blood products

     (a) Coagulation factors

     (b) Growth factors

     (c) Probable use of precursor cells for transfusion to patients

   ii) Pharmacological treatments

     (a) Studying, developing, preparing, and applying Bioorganic components

     (b) Investigating the use of small molecules

     (c) Investigating the side effects of current treatments

   iii) Blood stem cells

     (a) Blood stem cell transplant

     (b) Feasibility study of making universal donor hematopoietic stem cell

     (c) Making the required cell products for patients

   iv) Gene therapy

     (a) Investigating the use of gene therapy in Hereditary Blood Disorders

     (b) Investigating and improvement of side effects of treatment

Current activities

- Employing faculty members

- Preparing and publishing papers

Research Priority

1. Investigating the frequency of major Hemoglobinopathies in the region

2. Determining the alpha and beta thalassemia mutations using NGS and making relationship with foreign research centers

3. PND and determining the problems and deficiencies

4. Investigating the molecular defects of coagulation diseases and specialized coagulation tests

5. Investigating the prognosis factor in leukemia

Research Ethics

    31 Codes of Ethics

1. The main goal of every research must be to promote the health, dignity, and rights of human subjects.

2. If the research involves human subjects, their health and safety is prior to every other benefits during and after the study

. 3. Doing study on human samples is justifiable when its potential benefits for them exceeds the dangers

4. Issues such as speed, simplicity, convenience of the researcher, lower cost, or practicality must never put the samples in danger or harm, or impose any limitations on them.

5. Before setting up any kind of medical research, everything to minimize the probable harms to the samples should be done and their health must be guaranteed.

6. In double-blinded clinical trials in which the human samples are not aware of the prescribed drug or intervention, the researcher must be prepared to help them in emergency.

7. The research must be stopped immediately if the researcher recognizes that the dangers exceed the potential benefits.

8. Designing and implementing the studies on human samples must be based on the up-to-date approved scientific rules as well as the comprehensive review of the scientific sources of previous laboratory studies on animals.

9. Required cautions must be considered to maintain the environment in medical studies, which may harm it.

10.All the research projects must be based on a proposal.

11.In addition to assessing and approving the proposals, Research Ethics Committee has the right to monitor the research projects during and after the implementation for ethical considerations.

12. The potential samples should be fairly chosen and load distribution of dangers and cost must not be discriminately divided in the population.

13.It is necessary to get freely-given informed consent in every research done on human samples.

14.If any change in the process of doing the research is made or new information is achieved that may affect the decision of the samples in continuing their participation, it should be informed to the Research Ethics Committee. If the committee decides that the research can continue, the samples should be informed about it and a second informed consent should be got.

15.The researcher must ensure that the obtained consent is informed.

16.The researcher must ensure that the obtained consent is freely-given.

17.The main researcher is responsible for presenting adequate and understandable information to the samples and obtaining informed consent.

18.For medical research using identifiable human material or data, such as research on material or data contained in biobanks or similar repositories, the researcher must seek informed consent for its collection, storage, and/or reuse.

19.The refusal of a patient to participate in a study or the patient’s decision to withdraw from the study must never 

Partner organizations

1. Thalassemia Research Center

2. Cellular and Molecular Research Center

3. Pharmaceutical Sciences Research Center

Members Directory

Members of the Council

Members of the Center

Contact us

Please note

We do not provide medical advice or referrals to practitioners. Decisions about medical care and treatment should be made in consultation with a health care provider, based on the condition and needs of each person

The phones are monitored Saturday through Wednesday from 09:00 a.m.– 14:00 p.m.

Telephone: +98 - 01142316319 - 01142218231

Fax: +98 01142316319

Email: ho.ranjbaran@gmail.com

Address: Hemoglobinopathy Institute – Bu-Ali Sina Hospital – Pasdaran Boulevard – Sari , Mazandaran, Iran